1 terminated. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
Follow PY159 Single agent dose level 1: new trials by email Literature Review of PY159 Single agent dose level 1 trials Research Report on PY159 Single agent dose level 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3 - Advanced Solid Tumor, Gynecologic Cancer | Phase 1 | Terminated | Ikena Oncology | 127 | 2020-11-10 | 2024-03-22 |
Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Pancreatic Neoplasms (1)
Ikena Oncology (1)
United States (1)
Len Reyno, MD (1) · Marc Chamberlain, MD (1)